Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Analysts are intrested in these 5 stocks: ( ($MRK) ), ( ($REGN) ), ( ($CLRB) ), ( ($HUMA) ) and ( ($FL) ). Here is a ...

Replimune Group shares fell 28% on heavy volume with no news, despite a promising July 2025 PDUFA date for RP1 in advanced ...

Regeneron's lead counsel was Jonathan D. Polkes of White & Case LLP.

MAIA Biotechnology, Inc. , a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract about the efficacy data from the Phase ...

As of mid-May 2025, the S&P 500 has turned positive year-to-date (YTD) for the first time in many weeks. Stocks across ...